# Supplementary Material of "Quality of life in head and neck cancer survivors: the Big Data for Quality of Life study"

- 1 Mauricio Moreira-Soares<sup>1\*</sup>, Erlend I. F. Fossen<sup>1</sup>, Katherine J. Taylor<sup>2</sup>, Susanne Singer<sup>2</sup>,
- 2 Katrina Hurley<sup>3a</sup>, Steve Thomas<sup>3b</sup>, Miranda Pring<sup>3b</sup>, Andrew Ness<sup>3b</sup>, Stefano Cavalieri<sup>4,5</sup>,
- 3 Claudia Vener<sup>6</sup>, Laura Lopez-Perez<sup>7</sup>, Maria Fernanda Cabrera-Umpierrez<sup>7</sup>, Giuseppe Fico<sup>7</sup>,
- 4 Arnoldo Frigessi<sup>1,8</sup>, Lisa Licitra<sup>4,5</sup>, Marissa LeBlanc<sup>1,9</sup>, on behalf of the BD4QoL consortium
- <sup>5</sup> <sup>1</sup> Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway
- <sup>2</sup> Institute of Medical Biostatistics, Epidemiology, and Informatics, University Medical Centre
  Mainz, Germany
- 8 <sup>3</sup> Bristol Head & Neck 5000 Study, 3a University Hospitals Bristol and Weston NHS Foundation
- 9 Trust, Bristol, UK, 3b Bristol Dental School, University of Bristol, United Kingdom
- <sup>4</sup> Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,
  Milan, Italy
- <sup>5</sup> Department of Oncology and Hemato-oncology, University of Milan, Italy
- <sup>6</sup> Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
  Milan, Italy
- <sup>7</sup> Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, Madrid,
  Spain
- <sup>8</sup> Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway
- 18 <sup>9</sup> Norwegian Institute of Public Health, Oslo, Norway

# 19 \* Correspondence:

- 20 Corresponding Author
- 21 m.m.soares@medisin.uio.no
- 22
- 23
- \_\_\_\_
- 24
- 25
- 26
- 27
- 28
- 29
- 30

#### 31 1 **Supplementary Material**

#### 32 1.1 **Data harmonization**

### 33 Differences and commonalities in the studies variables

34 We observed high heterogeneity with respect to variables collected across studies. For instance, the

35 UMM data contain a broad range of variables with detailed information about treatment tolerance,

clinical devices used, welfare status such as sick leave and EU pension applications, among many 36

other demographic and socioeconomic indicators. On the other hand, the INT data focus mainly on 37

38 clinical information. The UoB data present a mix of clinical information and OoL data with several 39

different questionnaires. We integrated basic clinical characteristics, demographics, and two quality-40 of-life questionnaires that were present in all datasets, the EORTC QLQ-C30 and the head and neck

41 module EORTC QLQ-H&N35. For variables that were not completely equivalent and presented

42 different levels of details, e.g., education level, household income, and marital status, we reduced

43 their granularity to allow comparable measurements.

## 44 Time-to-event data

45 The UMM2 and UMM3 studies were not intended to model survival, so only interval-censored data

46 with right censoring are available. Patients' statuses were checked at scheduled timepoints, but times

47 of death were not recorded. All patient statuses were measured at baseline, so left censoring is not

48 present in the data. UMM1 provided vital information for 83% of the subjects (N=181) from study

49 enrollment (before treatment) up to 12 years. We found no significant differences between the groups

50 with measured and missing vital information age, sex, tumor location, tumor stage, income, and

51 education level, using a univariate logistic regression model approach where the response variable is 52

the binary indicator "missing vital information" (yes/no). Therefore, we assume that the vital

53 information is missing completely at random (MCAR) due to the data collection procedure, which 54 involved retrieving vital information for each patient directly from clinicians many years after the

55 study's conclusion. INT provided the time of death/censoring from study enrollment (before

56 treatment) up to two years. UoB provided survival data with time of death/censoring from the time of

study enrollment (before treatment). Participants' statuses were checked every 6 months from UK 57

registry data up to 6 years after study enrollment. The survival data for INT, UMM1, and UoB were 58

59 aligned and shifted to the BD4QoL baseline (after treatment), which consisted of a 6-month shift for

INT, 4 months for UMM1, and 12 months for UoB. 60

61

#### 2 62 **Supplementary Figures and Tables**

- 63
- 64 **Supplementary Figures** 2.1



- 66 Figure S1 Missing patterns in the EORTC QLQ-C30 subscales at baseline. Each row
- 67 identifies a variable and each column a missing pattern. The figure displays the number of
- 68 cases with a given pattern in the top of each column and the respective number of missing
- 69 variables in the bottom. The two biggest groups are the ones completely missing the
- 70 questionnaire (N=1692) and the ones with complete questionnaire (N=2363), followed by
- 71 survivors with available GHS/QoL and any other missing subscale (N=312) and survivors with
- 72 missing GHS/QoL and any other subscale available (N=82).



75 Figure S2 EORTC QLQ-C30 functional and symptoms scales histograms.



77 Figure 3 - EORTC QLQ-H&N35 scales histograms.



Figure S4 – INT cohort inclusion flowchart.

6















Figure S7 - UMM3 cohort flowchart.



90 91

Figure 8 - HN5000 cohort flowchart.